

Workshops: 27th April 2010 | Conference: 28th and 29th April 2010
Location: Marriott Courtyard Frankfurt Messe, Frankfurt, Germany


Book by
February 19th
and save up to
€400

Vaccine Innovation

Business Growth Through Innovation in Vaccine R&D

Meet and learn from the world's most innovative and successful big pharmaceutical and biotech companies in vaccine development.

- Assess how the latest developments in next generation vaccines are set to dramatically change the industry, with insights from **Dr Jeffrey Ulmer** of **Novartis** and **Dr Danilo Casimiro** of **Merck**.
- Explore the role of novel adjuvant technologies, including an outline from **Dr Heather Davis**, Executive Director at **Pfizer**, discussing **advanced strategies in adjuvant research** for creating more effective vaccines.
- Discover how **Novartis** are using **surface protein analysis in antigen discovery and engineering** as a fast track to finding more effective vaccines.
- Hear the latest developments in **structure-based approaches** from the likes of **Transgene**, **Okairos** and **Cytos Biotechnology**.
- Vaccine industry pioneer and founder of **Intercell**, **Dr Alexander Von Gabain**, gives his appraisal on how you can **overcome the barriers to innovative vaccine development**.
- Get the **latest investment perspectives** from the leading pharmaceutical companies in the vaccine field, as **Sanofi-Pasteur**, **Merck Serono** and **Pfizer** debate how you can make your vaccine research more attractive to potential investors.
- Developing a **universal flu vaccine** remains a holy grail for many vaccine researchers. **Dr George Kemble**, Vice President, Vaccine Research & Development, **MedImmune**, outlines his vision for how the industry can achieve this goal.



PRE-CONFERENCE WORKSHOP

April 27th 2010 - 13.30

Capitalizing on Patents and Other IP Rights
Strategies for the protection of vaccines

WORKSHOP LEADER

Dr Gerd Stoetter, European Patent Attorney, **Kailuweit & Uhlemann**

Hear 24 of the world leading vaccine experts

- **Dr Jeffrey Ulmer**, Global Head of External Research, **Novartis Vaccines and Diagnostics**
- **Dr Kathrin Jansen**, Senior Vice President, Vaccine Research and Early Development, **Pfizer**
- **Dr Danilo Casimiro**, Director and Head, Viral Vaccine Research, Vaccine Basic Research, **Merck & Co.**
- **Dr Andrew Murdin**, Senior Director External Research and Development, **Sanofi-Pasteur**
- **Dr George Kemble**, Vice President, Research and Development, **MedImmune**
- **Dr Jens-Oliver Funk**, Senior Vice President, Global Head of Therapeutic Area Oncology, **Merck Serono**
- **Dr Alexander von Gabain**, Strategic Advisor to the Management and Supervisory Boards, **Intercell AG**
- **Dr Jean-Yves Bonnefoy**, Vice President Research and Development, **Transgene**
- **Dr Jessica Flechtner**, Senior Director Research and Development, **Genocea Biosciences**
- **Dr Jerald Sadoff**, President and Chief Executive Officer, **Aeras Global TB Vaccine Foundation**
- **Dr Christoph Huels**, Vice President Early Stage Licensing, **Merck Serono**
- **Dr Thomas Hofstaetter**, Chief Operations Officer, **VaxInnate**
- **Grant Pickering**, Chief Executive Officer, **Juvaris Biotherapeutics**
- **Dr Martin Bachmann**, Chief Scientific Officer, **Cytos Biotechnology**
- **Dr Christian Moser**, Head of Research, **Pevion Biotech**
- **Dr Kingston Mills**, Co-founder, **Opsona Therapeutics Ltd**
- **Dr Steen Klysner**, Chief Executive Officer, **Nordic Vaccine**
- **Dr Alfredo Nicosia**, Chief Scientific Officer, **Okairos**
- **Dr Michael Wacker**, Chief Scientific Officer, **GlycoVaxyn**
- **Dr William Enright**, Chief Executive Officer, **Vaxin**
- **Paul Radspinner**, Chief Executive Officer, **Flugen**
- **Dr Heather Davis**, Executive Director and Ottawa Site Head, Vaccine Research, **Pfizer Global Research & Development**
- **Dr Guido Grandi**, Senior Project Leader, **Novartis Vaccines and Diagnostics**
- **Dr Jon Heinrichs**, Senior Research Fellow, **Merck & Co.**

Sponsors



Media Partners



To register: www.vaccine-innovation.com • Email at register@hansonwade.com
Tel at +44 (0) 203 141 8700 • Fax at +44 (0)20 7222 2685



DELIVERING BUSINESS GROWTH THROUGH INNOVATION IN VACCINE R&D

Are you positioned to capitalise on the unprecedented boom in vaccine innovation? With the first of many successful new vaccines hitting the market, **Vaccine Innovation** represents an outstanding opportunity to evaluate innovative new technologies and processes, and understand the tangible difference they can make to both your business and research.

Vaccine Innovation will cover challenges and opportunities identified by key big pharmaceutical and biotech companies in innovating novel vaccines:

- Explore new ways to develop vaccines using the **latest developments in antigen discovery and engineering**, with insights from **Novartis, Merck** and **Genocea Biosciences**.
- **Pfizer, Sanofi Pasteur** and **Merck Serono** discuss fast-changing attitudes towards innovation in the vaccines industry, and **what you can do to make your business and research more attractive to potential partners and investors**.
- Understand the latest cutting edge developments in **adjuvant technology**, and how you can use **new classes of adjuvants to greatly enhance the immunogenicity** of your vaccine candidates.
- **Transgene, Okairos** and **Cytos Biotechnology** outline how to apply **structure-based approaches** to create innovative new vaccines with **increased potency and greater therapeutic potential**.
- Assessing the near term potential of **next generation vaccines** is critical to any vaccines business. Listen to **MedImmune, Novartis** and **Merck** outline their vision and current activities in developing novel, game-changing vaccines that will revolutionize the industry.
- Learn from the success of **Pfizer** and **Merck Serono** as they demonstrate **how to take promising early stage vaccine research successfully into the clinic**.
- Finding **alternatives to needle-based delivery** of vaccines is driving innovation in the industry. Find out how **novel methodologies for vaccine design and delivery** can create new growth opportunities for your business.

Register now and realise the true commercial potential of your vaccine research.

Invaluable feedback on your vaccine R&D

The quality and rate of innovative research and development in vaccines has increased dramatically in the last few years.

As part of the Biorbis mission to accelerate progress and encourage dialogue, **we encourage attendees to present a poster**.

Presenting a poster is **free of charge** to all registered delegates. Please note that poster displays may not be used for sales or marketing purposes, and all poster abstracts are subject to approval by the conference organisers.

Just tick on the booking form or inform us when registering.

Contact Richard Lumb at Richard.lumb@hansonwade.com for more details

Be ready to talk about your work and don't forget to bring plenty of business cards.

Who Should Attend

Vaccine Innovation is an elite meeting of international scientists and research leaders from the major vaccine pharmaceutical companies and foremost biotechs. **Directors and Heads of Vaccine R&D, Chief Executive and Scientific Officers, research leaders and scientists** will all benefit and have the opportunity to debate issues at the cutting edge of vaccine research.

Grab the chance to come along and speak to the most innovative biotechs in the sector and forward-thinking research establishments. Make the most of opportunities for **face-to-face dialogue** during our **interactive and networking sessions** and converse with the other attendees as well as the skilled speaker faculty. Just be ready to talk about your work and don't forget to bring plenty of business cards.



Biorbis is on an **unrelenting mission** to deliver scientific meetings to the business and research community that will **accelerate progress and ultimately benefit patients**.

Our focus is on discovering what makes a difference to your research or business, and working with you to design highly relevant, cutting-edge agendas with content delivered by globally recognised experts and leaders in the field.

We create an environment that encourages open dialogue, frank discussion, generation of ideas and exchange of information that will help to advance medical science and improve your research or grow your business.

www.biorbis.com

CONFERENCE DAY ONE: Wednesday 28th April 2010

08.30 Registration, coffee and networking

09.00 **Chairperson's Opening Remarks**
Dr Jerald Sadoff, President and Chief Executive Officer,
Aeras Global TB Vaccine Foundation

09.05 **KEYNOTE PRESENTATION: Key Drivers of Innovative Vaccine Development: Global Challenge of Infectious Diseases and Progress in Technology**

- The global threat of existing and novel infectious diseases
- Scientific progress and new technology enable to target novel microbial diseases
- New horizons for antigens, adjuvants and delivery systems
- Alliances between academia, biotech, big pharma and nonprofit organizations move vaccines forward

Dr Alexander von Gabain, Strategic Advisor to the Management and Supervisory Boards, **Intercell AG**

09.35 *** SPEED NETWORKING SESSION ***
 Don't miss this fantastic opportunity to meet other meeting attendees

10.35 Morning refreshments

ANTIGEN DISCOVERY AND ENGINEERING

11.00 **Surface Protein Analysis: A Fast Track to Vaccine Discovery**

- Identification of surface-associated proteins in gram+ive and gram-ive bacteria
- Identification of immunogenic surface proteins
- Quantification of surface protein expression level
- Selection of proteins eliciting protective immunity

Dr Guido Grandi, Senior Project Leader,
Novartis Vaccines and Diagnostics

11.30 **An Innovative Approach to Harness the Power of T-cells to Identify Protective Vaccine Antigens**

- Genocea identifies novel targets for vaccines for unmet medical needs based on natural immunity after infection
- The approach is rapid and unbiased – every protein from a pathogen is screened to identify which serve as antigens
- Antigens are prioritized based on defined clinical outcomes from multiple ethnic groups
- Genocea's technology accelerates the vaccine discovery phase from years to months

Dr Jessica Flechtner, Senior Director, Research and Development,
Genocea Biosciences, Inc.

12.00 **Identification and Evaluation of Vaccine Candidates for the Prevention of Staphylococcus aureus Infections**

- Identification of vaccine candidates from the staphylococcal genome
- Validation of vaccine targets in animal models
- Clinical evaluation of IsdB, a protein vaccine for S. aureus

Dr Jon Heinrichs, Senior Research Fellow, **Merck & Co**

12.30 Lunch and poster session

APPLYING STRUCTURE BASED APPROACHES TO CREATE INNOVATIVE NEW VACCINES

13.30 **Viral-based Therapeutic Vaccines: Recent Achievements**

- Scientific rationale and synergy with other cancer treatments
- Clinical results
- Biomarker signatures

Dr Jean-Yves Bonnefoy, Vice President Research and Development, **Transgene**

14.00 **Designing Smarter Adenoviral Vector Delivery of Vaccines: What has Translated Successfully into Humans?**

- How can adenovirus delivery proceed at this time given the bad result with HIV?
- Can animal studies predict the immunogenicity of different

- adenovirus vectors in humans?
- Is there a better alternative to the currently used cell substrates for adenovirus vector production?
- Are there better vector combinations for vaccine delivery?

Dr Alfredo Nicosia, Chief Scientific Officer, **Okairos**

14.30 **Advances in Research Methodology for Vaccination Against Type II Diabetes**

- Anti-IL-1b vaccination
- Preclinical and first clinical data
- Cytokine neutralisation

Dr Martin Bachmann, Chief Scientific Officer, **Cytos Biotechnology AG**

15.00 Afternoon refreshments

NEXT GENERATION VACCINES

15.30 **New Technologies for Improved Vaccines**

- Antigen discovery
- Rational approaches to antigen development
- Novel adjuvants and delivery systems

Dr Jeffrey Ulmer, Global Head, External Research, **Novartis Vaccines & Diagnostics**

16.00 **Glycoengineered Yeast as a Novel Platform for the Development of Subunit Vaccines**

- Development of *Pichia* strains capable of incorporating human N-glycans/immunomodulatory glycans
- Construction of herpes virus glycoprotein immunogens in glycoengineered yeast strains
- Comparative immunogenicity and efficacy of immunogens derived from glycoengineered strains in preclinical challenge models

Dr Danilo Casimiro, Director and Head, Viral Vaccine Research, Vaccine Basic Research, **Merck & Co**

16.30 **Live Attenuated Influenza Vaccine Technology: Applications for Seasonal and Pandemic Influenza Preparedness and Prevention**

- Biological properties of live attenuated influenza vaccines (LAIV)
- Recombinant DNA technologies used to construct live attenuated influenza vaccine
- Performance of seasonal LAIV
- Preclinical and clinical studies of model pandemic LAIV

Dr George Kemble, Vice President, Vaccine Research & Development, **MedImmune**

17.00 **Paradigm Shift in Discovery and Production of Glycoconjugate Vaccines**

- GlycoVaxyn has developed a proprietary technology that allows the production of conjugated vaccines (bioconjugates) in bacterial cells
- Complete in vivo process, no toxic cells required for production of these bioconjugates
- Polysaccharide independent conjugation, high homogeneity due to enzymatic process
- Bioconjugates are immunogenic and functional in animals

Dr Michael Wacker, Chief Scientific Officer, **GlycoVaxyn AG**

17.30 **Panel Discussion: What is the Future of Vaccines?**

- What needs to be done to generate effective vaccines for HIV, pandemic flu and other chronic diseases?
- Strategies for developing vaccines for the developing world
- What is the 5 year/10 year forecast for the vaccine industry

Dr Jerald Sadoff, President and Chief Executive Officer, **Aeras Global TB Vaccine Foundation**
Dr Alexander von Gabain, Strategic Advisor to the Management and Supervisory Boards, **Intercell AG**
Paul Radspinner, Chief Executive Officer, **Flugen**

18.00 Chairman's Closing Remarks, Poster Session and Networking

CONFERENCE DAY TWO: Thursday 29th April 2010

08.30 Registration, coffee and networking

09.00 **Chairperson's Opening Remarks**
Dr Jeffrey Ulmer, Global Head, External Research,
Novartis Vaccines & Diagnostics

DEVELOPING BETTER ADJUVANTS TO OVERCOME POOR IMMUNOGENICITY

09.05 **Adjuvants and Delivery Systems for Enhancing Specific Responses to Prophylactic and Therapeutic Vaccines**

- Use of TLR agonists alone, together and with delivery systems
- Selection of adjuvant combinations to drive humoral and/or cell-mediated immunity
- Translation from animal models to humans

Dr Heather Davis, Executive Director & Ottawa Site Head, Vaccines Research, **Pfizer Global Research & Development**

09.35 **Utilising RNA: A Safe and New Route to More Effective Vaccines**

- Self-adjuvanted mRNA induces 'balanced', i.e. humoral and cellular immune responses' involving toll-like receptor activation
- Vaccines derived from self-adjuvanted mRNA exert anti-tumor effects as well as protection against viral infections
- RNA adjuvants strongly enhance the efficacy of approved adjuvanted and non-adjuvanted vaccines

Dr Karl-Josef Kallen, Chief Scientific Officer, **CureVac**

10.05 **How to use Toll-like Receptors in Vaccinology: Triggering a Robust Immune Response**

- Development of strongly immunogenic vaccines without classical adjuvants
- Utilising pathogen associated molecular patterns to design novel vaccines

Dr Thomas Hofstaetter, Chief Operations Officer, **VaxInnate**

10.35 Morning refreshments

11.00 **Adjuvant Modulation of Innate Immunity to Selectively Promote Protective T Cell Responses**

- Role of effector and regulatory T cells in immunity to infection
- Role TLR agonists and other adjuvants in directing T cell responses
- Activation of the inflammasome by adjuvants and its role in driving Th17 cells
- Enhancing the efficacy of vaccines adjuvants by inhibiting Treg cells

Dr Kingston Mills, Co-founder, **Opsona Therapeutics Ltd**

11.30 **Novel Approaches to Harness the Power of T-cells Boosting the Immune Response**

- Harnessing adjuvants to improve vaccine delivery and immunopotential
- Tapping the power of polyfunctional T-cell responses

Grant Pickering, Chief Executive Officer, **Juvaris BioTherapeutics**

12.00 **Virosomes: More than just a Delivery Technology**

- Adjuvant and carrier system for subunit vaccines
- Modular Virus-Like Particle assembled in vitro
- GMP production at industrial scale established and validated
- Clinical safety track record with >50 million vaccine doses
- Functional and long-lasting antibody responses in man with 10 micrograms peptide/dose

Dr Christian Moser, Head Research, **Pevion Biotech**

12.30 Lunch

ATTITUDES TO INNOVATION – A PHARMACEUTICAL PERSPECTIVE

13.30 **Panel discussion: Pharma Leaders in R&D – Attitudes to Innovation**

- A discussion about what the big pharmaceuticals are looking for in an investment
- What can biotechs do make themselves an attractive opportunity.

Dr Heather Davis, Executive Director & Ottawa Site Head, Vaccines Research, **Pfizer Global Research & Development**
Dr Christoph Hüls, Vice President Early Stage Licensing, **Merck Serono**
Dr Andrew Murdin, Senior Director External Research & Development, **Sanofi-Pasteur**

NOVEL METHODOLOGIES FOR VACCINE DESIGN & DEVELOPMENT

14.00 **Transcutaneous Delivery, an Alternative to Needle-based Immunisation**

- Features of Skin immunity
- Lessons from Transdermal Drug delivery
- Current approaches to Transcutaneous immunization
- TransVacTM : A novel skin patch vaccine delivery system

Dr Steen Klysner, Chief Executive Officer, **Nordic Vaccine**

14.30 **Non-invasive Vaccine Delivery to Elicit an Immune Response**

- Intranasal route of administration appears to offer advantages in both efficacy and ease of use
- Innovative molecular vaccines allow rapid, efficient, high yield, cell culture based manufacturing
- Promising Ph I data with intranasally administered influenza vaccines
- Solid protection in multiple animal models with single intranasal administration of anthrax vaccine

Dr William Enright, Chief Executive Officer, **Vaxin**

15.00 Afternoon refreshments

INNOVATIVE VACCINES IN THE CLINIC

15.30 **Therapeutic Cancer Vaccines in Combination with Other Treatments - New Paradigms for Clinical Trials**

- The paradigm shift in therapeutic cancer vaccines will be described
- Implications of vaccine combination with standard of care therapies
- The impacts on clinical trial design and endpoints
- Case studies of current cancer vaccines will be presented

Dr Jens-Oliver Funk, Senior Vice President, Merck Serono R&D, Global Head of TA Oncology, **Merck KGaA**

16.00 **Considerations to Vaccine Development**

- Promising results in vaccine development: Lessons learned
- Overcoming the barriers in vaccine research

Dr Kathrin Jansen, Senior Vice President, Vaccine Research & Early Development, **Pfizer**

16.35 Chairman's Closing Remarks

INTERACTIVE WORKSHOP

CAPITALIZING ON PATENTS AND OTHER IP RIGHTS

TUESDAY APRIL 27th 2010 13.30-16.30

Capitalizing on Patents and other IP rights: Strategies for Protection of Vaccines

This workshop will address the role of intellectual property in vaccine design and development, both from the perspective of research into vaccine technology and the development of vaccine-based products.

Using landmark case studies we will discuss the key areas of intellectual property law ensuring that you leave fully armed with all the knowledge and contacts you need to develop your vaccine candidates. In particular, the workshop will address:

- Navigating the patent application process to ensure your invention is protected
- What can be protected – natural substances, biological matter, vaccine technology, research tools
- Safeguarding key innovations & developing strong vaccine portfolios

We will also consider the ways in which you can ensure that your product is protected on a global scale as well as touching on current strategies in patent protection giving you a unique insight into what your competitors are doing. The second half of the workshop will examine:

- Differences in the US and European patent systems
- What possibilities exist for alternative and flanking protection of vaccines
- Emerging trends in pharmaceutical patenting and intellectual property



Workshop Leader: Dr Gerd Stötter, European Patent Attorney
Kailuweit & Uhlemann

Gerd Stötter is a biochemist and German and European Patent Attorney with a strong scientific background in immunology and protein chemistry. After studying in Berlin and Montpellier (France) he worked at the Netherlands Cancer Institute in the field of immunology and at the University of Zurich in computer-aided drug design. Since 2006 he

has been a partner at the patent and trademark law firm of Kailuweit & Uhlemann. Gerd has widespread experience in all areas of life sciences patenting, including prosecution, opposition and litigation. He has advised biotech start-ups, pharmaceutical companies, universities and research institutions in value generation using Intellectual Property Rights. Gerd specializes in immunology and biotechnology.



Workshop Leader: Dr Maria Fischer, Trainee Patent Attorney
Kailuweit & Uhlemann

Dr. Maria Fischer studied Biotechnology at the Technical University Berlin and Dongseo University Busan, South Korea, specialising in drug targeting and immunology. In 2005 she graduated with a diploma in engineering and a MSc. She worked at the Charite Berlin and the German Rheumatism Research Center studying the induction pathways of autoimmune diseases by distinct bacterial pathogens. After finishing her PhD in 2009 she started her work as a patent attorney trainee at the patent and trademark law firm of Kailuweit & Uhlemann in Dresden. Maria's areas of expertise are pharmacology, biotechnology, biochemistry, molecular biology, drug design and immunology.

OFFICIAL PARTNER

CureVac is a biopharmaceutical company pioneering the direct therapeutic application of messenger RNA (mRNA) the biomolecule that physically transfers genetic information from the nucleus to the cellular protein production machinery. By making mRNA available for therapeutic purposes, **CureVac** seeks to introduce a novel class of drugs into today's medicine.



Building on a unique body of knowledge in RNA research, design and cGMP production, the Company has established a range of proprietary technologies. These include: **RNAActive®** for the design of modified and formulated mRNA targeting a broad range of therapeutic applications, **RNAduvant®** for the use of RNA as an immune stimulant, **PUREmessenger®** for the GMP-production of long-chain mRNA up to 15.000 nt. Based on these technologies, the Company is building a growing pipeline of innovative product candidates.

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

For the first time in years, new technological advances in vaccine research and development are set to revolutionise the industry. It's not easy to get productive face time with the most successful players in the vaccines market. Companies developing new technologies, equipment or other service offerings who can put themselves in front of innovative big pharma and biotech companies are set to capitalise for years ahead.

Achieve this foothold in the vaccines industry, or cement your position as the partner or supplier of choice. Sponsor or Exhibit at Europe's most influential vaccine innovation meeting! Your next partners, prospects and clients will be there. Will you?

Why wait? The earlier we confirm your involvement, the sooner we can include you in our marketing campaign and expose your company to our extensive database of vaccine business and research contacts.

Contact **Miles Harley**
on + 44 (0)203 141 8701
or email miles.harley@hansonwade.com

Vaccine Innovation

Workshops: 27th April 2010 | Meeting: 28th and 29th April 2010

Venue: Marriott Courtyard Frankfurt Messe, Frankfurt, Germany



A division of
Hanson Wade

Priority Code: 597 - WEB

TEAM DISCOUNTS

Book with a colleague and claim your discount:

• 10% discount – 3 delegates

• 15% discount – 4 delegates

• 20% discount – 5 or more delegates

* Please note that discounts are only valid when three or more delegates from one company book and pay at the same time

PURCHASE CONFERENCE DOCUMENTATION

If you are unable to attend, you may purchase the conference documentation for €550.

You will receive the documentation immediately after the conference.

Documentation orders can only be processed on receipt of credit card details

VENUE & ACCOMMODATION

ACCOMMODATION

Courtyard Frankfurt Messe

Oeserstrasse 180

Frankfurt, Hessen 65933

Germany

T: +49 69 3905 0

Accommodation is not included in the registration fee. To book a room at the Courtyard Frankfurt Messe, please contact the hotel directly on +49 69 3905 17 or email maren.miketta@courtyard.com

SPECIAL REQUIREMENTS

If you have any special dietary requirements or other needs that would enhance your enjoyment of this event, please contact us in advance and we will make every effort to assist you.

TERMS & CONDITIONS

Full payment is due on registration.

Cancellation and Substitution Policy:

Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda:

Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection:

The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes.

If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13 - 15 Carteret Street, London, United Kingdom, SW1H 9DJ.

Tel: +44 203 141 8700. Email: info@hansonwade.com

Hanson Wade Limited. Registered in England & Wales.
Company No: 6752216

HOW TO REGISTER

Online: www.vaccine-innovation.com

Fax: +44 (0)20 7222 2685

Tel: +44 (0)20 3141 8700

Mail: Hanson Wade

Charter House

13 - 15 Carteret Street

London, United Kingdom

SW1H 9DJ

Email: register@hansonwade.com

REGISTRATION FEES

	Pay by February 19th 2010	Pay by March 12th 2010	Standard Price
<input type="checkbox"/> Conference + Workshop	€2199 + VAT SAVE €400	€2399 + VAT SAVE €200	€2599 + VAT
<input type="checkbox"/> Conference Only	€1599 + VAT SAVE €400	€1799 + VAT SAVE €200	€1999 + VAT
<input type="checkbox"/> Workshop Only	€599 + VAT	€599 + VAT	€599 + VAT
<input type="checkbox"/> Conference documentation	€550 + VAT		

* To qualify for discounts payment must be received by the registration deadline. Early booking discounts are not valid in conjunction with any other offer.

* VAT will be charged at 19%. The conference fee includes lunch, refreshment course documentation. This fee does not include travel or hotel accommodation.

DELEGATE DETAILS

Please complete fully and clearly. Please photocopy for additional delegates.

Title:	Forename:
Surname:	Job Title:
Company/Organisation:	
Email:	Direct Manager:
Address:	
Postcode:	Country:
Direct Telephone:	Direct Fax:
Mobile:	Switchboard:
Signature:	Date:

HOW TO PAY

Number of delegates Amount: €

Conference Documentation ☐

Credit Card: ☐ Visa ☐ Mastercard ☐ Maestro ☐ Amex

Card No:

Valid from: / / Expiry Date: / /

Cardholders name

Signature: Date:

Card billing address

☐ **CHEQUE** Enclosed is our cheque for € made payable to: Charter House, 13 - 15 Carteret Street, London, United Kingdom, SW1H 9DJ

☐ **BANK TRANSFER** Please quote your company name as transfer reference
HSBC Bank. Account name: Hanson Wade Ltd. Account No. 69121000
Sort Code: 40-05-15. Swift Code : MIDLGB22. IBAN: GB98MIDL40051569121000.
Address: 5 Wimbledon Hill Road, Wimbledon, London, SW197NF

CODE: 597 - WEB